Equity Pricing in the Real World: Moving from Ambiguity to Action for Patients, Payers, and Health Systems Aligning equitable access and commercial sustainability is one of the Read More »
Navigate access policies Equity Pricing in the Real World: Moving from Ambiguity to Action for Patients, Payers, and Health Systems Read More August 20, 2025
Navigate access policies Japan’s Drug Pricing Debate: Abolishing Off-Year Revisions to Restore Market Stability Read More August 18, 2025
Navigate access policies US Pharmaceutical Tariffs: Exempt for Now, But for How Long? Read More June 30, 2025
Navigate access policies How IRA Negotiations Are Shaping US-EU Drug Price Differentials Read More March 26, 2025
Navigate access policies The Impact of Access Policies on Biosimilar Pricing in Five Major EU Markets Read More March 18, 2025
Price Your Asset Right Review on the effectiveness of Japan’s FY2024 reform on NHI price listing Read More January 23, 2025
Price Your Asset Right Global Pharmaceutical Pricing and ESG: What Pharmaceutical Companies Can Learn From Marie Stella Maris Read More October 3, 2024
Define Your Value Strategy Cheers To Driving Global Access: 3 Lessons Pharma Can Learn From Heineken Read More April 9, 2024
Price Your Asset Right Exploring Net Price Dynamics of Orphan Drugs: EU4 and US Market Insights Read More April 2, 2024
Price Your Asset Right Navigating Multi-Indication Pricing in Germany and France Read More February 15, 2024
Navigate access policies Market Access: The Overlooked Dimension in ESG Reporting Read More December 8, 2023
Navigate access policies Will AI-powered bots replace Market Access professionals?  Read More October 9, 2023
Navigate access policies European Hospital Exemption Pathways for ATMPs : Implementation and Impact Read More September 21, 2023
Navigate access policies Using the Hospital Exemption Pathway to improve patient access to ATMPs in Europe Read More September 19, 2023
Define Your Value Strategy Fast-track reimbursement in Europe: Six reasons why manufacturers don’t use it Read More September 4, 2023
Define Your Value Strategy Five reasons why you need a strategic market access consultant Read More July 5, 2023
Communicate the value Global value dossiers are missing the access part of the story Read More June 23, 2023
Communicate the value A tailored approach to estimate the outlook of the gene therapy market Read More April 13, 2023
Define Your Value Strategy More than just price cuts: Improving access to essential cancer drugs in low and lower-middle-income countries Read More September 2, 2022
Navigate access policies How should pharmaceutical companies prepare for the upcoming joint EU HTA? Read More July 8, 2022
Navigate access policies France to Adopt a Market Access Pathway Like the German System Read More August 5, 2021
Define Your Value Strategy Unpacking the biotech sector: What sets this sector apart and what are the challenges Read More January 29, 2021
Navigate access policies Four Market Access Measures Triggered by COVID-19 That Are Here To Stay Read More August 25, 2020
Navigate access policies Reflections on The Initial Impact of COVID-19 on Global Market Access Activities Read More July 31, 2020
Price Your Asset Right 4 Take-Away Messages From The Zolgensma® Pricing Storm Read More July 4, 2019
